SBI Healthcare Opportunities (Equity, Equity Sectoral-pharma)

19 yrs 6 monthsStarted on:14 Jul 1999
₹ 1076.26 Cras on: 13 Dec 2018
Long Term Horizon
Capital Appreciation

Minimum Investment

  • ₹ 5000.00 for Lumpsum

Investment Objective

The scheme seeks to provide the investors with the opportunity of long-term capital appreciation by investing in a diversified portfolio of equity and equity related securities in Healthcare space.

Exit Load

Scheme Documents

Similar Funds
Reliance Pharma
Current NAV 1114.25
Return (CAGR) 20.47%
Crisil Ranking NA
Value Research NA
UTI Healthcare
Current NAV 1114.25
Return (CAGR) 13.10%
Crisil Ranking NA
Value Research NA


TenureReturns (CAGR)

SIP Returns

TenureReturns (CAGR)
10 YR13.36


Company Name% Assets
Aurobindo Pharma Ltd.11.3
Dr. Reddy's Laboratories Ltd.9.38
Sun Pharmaceutical Inds. Ltd.9.15
Strides Pharma Science Ltd.9.02
Divi's Laboratories Ltd.8.56
Lupin Ltd.6.59
Biocon Ltd.4.64
Torrent Pharmaceuticals Ltd.4.63
Alkem Laboratories Ltd.4.27
Glenmark Pharmaceuticals Ltd.4.25

Top Sectoral Holdings

Sector Name% Assets


Portfolio turnover ratio58
Standard Deviation16.74%

Tanmaya Desai

Mr. Desai is a B.E. (Electronics), MBA (Finance) and CFA (Level III).
Prior to joining SBI Mutual Fund he has worked with D.J. Sanghvi College of Engineering and Patni Computer Systems Ltd.
© CRISIL Limited 2017. All Rights Reserved